1. Home
  2. SSII vs CSTL Comparison

SSII vs CSTL Comparison

Compare SSII & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSII

SS Innovations International Inc.

HOLD

Current Price

$6.01

Market Cap

1.1B

Sector

N/A

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$40.31

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSII
CSTL
Founded
N/A
2007
Country
India
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SSII
CSTL
Price
$6.01
$40.31
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$46.00
AVG Volume (30 Days)
69.4K
333.2K
Earning Date
02-14-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,066,457.00
$343,530,000.00
Revenue This Year
N/A
$2.54
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
158.36
10.15
52 Week Low
$3.02
$14.59
52 Week High
$22.42
$42.18

Technical Indicators

Market Signals
Indicator
SSII
CSTL
Relative Strength Index (RSI) 52.25 57.91
Support Level $5.34 $38.73
Resistance Level $6.05 $41.60
Average True Range (ATR) 0.46 1.58
MACD 0.06 -0.12
Stochastic Oscillator 87.05 62.75

Price Performance

Historical Comparison
SSII
CSTL

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: